Go to Main NavigationGo to SearchGo to Main ContentGo to Footer Navigation
White wedge
The Campus Times logo
Last updated Tuesday, March 18, 2021 A Publication of the Office of Marketing & Communications

BHBP Biotech Firms Starts COVID-19 Vaccine Trials

Codagenix, the clinical-stage biotechnology company located at the Broad Hollow Bioscience Park on campus, has started human trials of a COVID-19 vaccine it hopes to be able to commercialize beginning in 2022.


In addition, Codagenix has secured a U.S. patent for a vaccine administered nasally to fight respiratory syncytial virus, or RSV.  


Robert Coleman, PhD, an associate professor of Biology at FSC, co-founded Codagenix, Inc. in 2012 to commercialize the genome design platform for vaccine development that he has previously co-invented.


Jeffrey Fu, chief business officer of Codagenix, told Newsday that the first doses in the double-blind, placebo-controlled study were administered to volunteers in London this month.


Last month, Codagenix secured the patent for a vaccine to fight RSV, a common respiratory virus that usually causes mild, cold-like symptoms. Many of those affected by RSV frequently recover within 7-14 days, but RSV remains a serious condition for certain populations. It can be especially serious for infants and older adults. 

Share by emailShare by email icon Share through FacebookFacebook logo Share through TwitterTwitter logo Share through LinkedInLinkedIn logo Share through PinterestPinterest logo
Previous Article
Celebrating Black History Month
Next Article
Introducing CircleIn, the All-In-One Studying Space